CASSAVA SCIENCES INC

For the period ended Dec 31, 2024. Filed Mar 3, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 3, 2025

FLNA$0.49+8.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Cassava Sciences, Inc.

(Registrant)

/s/ RICHARD J. BARRY

Richard J. Barry,

President, Chief Executive Officer and Director

(Principal Executive Officer)

Dated: March 3, 2025

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Robert Anderson, Jr.
Signature	Title	Date
/s/ RICHARD J. BARRY	President, Chief Executive Officer and	March 3, 2025
Richard J. Barry	Director
	(Principal Executive Officer)
/s/ ERIC J. SCHOEN	Chief Financial Officer	March 3, 2025
Eric J. Schoen	(Principal Financial Officer and Principal Accounting Officer)
/s/ ROBERT ANDERSON, JR.	Director	March 3, 2025
/s/ RICHARD J. BARRY	Director	March 3, 2025
Richard J. Barry
/s/ PIERRE GRAVIER	Director	March 3, 2025
Pierre Gravier
/s/ ROBERT Z. GUSSIN, PH.D.	Director	March 3, 2025
Robert Z. Gussin, Ph.D.
/s/ CLAUDE NICAISE, M.D.	Director	March 3, 2025
Claude Nicaise, M.D.
/s/ MICHAEL J. O'DONNELL, ESQ.	Director	March 3, 2025
Michael J. O'Donnell, Esq.
/s/ PATRICK SCANNON, M.D., PH.D.	Director	March 3, 2025
Patrick Scannon, M.D., Ph.D.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.